tiprankstipranks
Elite Pharmaceuticals Gains FDA Approval for Generic Vyvanse
Company Announcements

Elite Pharmaceuticals Gains FDA Approval for Generic Vyvanse

Pick the best stocks and maximize your portfolio:

Elite Pharmaceuticals ( (ELTP) ) has provided an update.

Elite Pharmaceuticals has secured FDA approval for a generic version of Vyvanse®, a widely-used treatment for ADHD, marking a significant opportunity in a market valued at $4.3 billion. With this approval, Elite is set to market the medication in various strengths under its Elite Laboratories brand, potentially boosting its presence in the pharmaceutical industry.

For an in-depth examination of ELTP stock, go to TipRanks’ Stock Analysis page.

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App